Aegerion Juxtapid Launch Targets Population Far Broader Than FDA Projection

Aegerion says feedback from key opinion leaders and market research indicate the market for its homozygous hypercholesterolemia drug may be as many as 3,000 patients; FDA estimates put the number at 315.

Aegerion Pharmaceuticals Inc. plans a January launch of its homozygous familial hypercholesterolemia drug Juxtapid (lomitapide) with a target population that appears to be broader than FDA expectations.

The total adjustable market for the drug could be as many as 3,000, CEO Marc Beers said during a Dec. 24 conference call. FDA, in announcing approval of Juxtapid, said...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America